Skip to main content
Premium Trial:

Request an Annual Quote

Tango Therapeutics Launches With $55M Series A Financing

NEW YORK (GenomeWeb) – Venture capital firm Third Rock Ventures has launched a cancer therapeutics firm called Tango Therapeutics with a $55 million Series A investment.

Tango said in a statement that it will use DNA sequencing and CRISPR/Cas9-based target discovery to provide improved therapies through three mechanisms: mutations that, when combined with the loss of a tumor suppressor, create a synthetic lethality; targeting multiple oncogenic driver mutations; and immuno-oncology.

"Loss of tumor suppressor genes is a hallmark of cancer, but the genes, themselves, are not tractable targets for drug discovery," Barbara Weber, interim CEO of Tango and a venture partner at Third Rock, said in a statement. "The availability of comprehensive DNA sequencing, coupled with CRISPR-enabled target discovery, provides us with new paths to identify novel drug targets and combinations that take advantage of vulnerabilities created by loss of tumor suppressor gene function — something we have been unable to do effectively in the past."

Among Tango's founders are José Baselga, Memorial Sloan Kettering Cancer Center's physician-in-chief; Alan Ashworth, president of the University of California, San Francisco's Comprehensive Cancer Center; and Timothy Lu, a synthetic biologist at the Massachusetts Institute of Technology. The firm will be headquartered in Cambridge, Massachusetts.

In December, Third Rock also helped launch a precision medicine company called Goldfinch Bio with a similar $55 million Series A financing round.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Develops Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.